Optimizing Drug Development with Model Informed Decision Making

Failure to demonstrate efficacy during phase 2 and/or phase 3 testing continues to be one of the primary reasons that drugs fail to progress through clinical development. Several areas that contribute to the success or failure of a trial could be addressed by an appropriate use of pharmacometric modeling and simulation techniques.

In this on-demand webinar, Tina Checchio, Associate Director of Strategic Consulting at Cytel highlights areas that are frequently supported by pharmacometric modeling and simulation, with a focus on the ways that strategic applications of pharmacometric approaches may be used to increase confidence at critical development milestones.

Key Learning Points

What is a model-informed decision?
How are pharmacometric modeling approaches applied in the industry to support these decisions?
What is the potential financial impact of using this type of approach within a development program?